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OBJECTIVE: The aim of this study was to evaluate the prevalence and spectrum of Nkx2.5 mutations associated
with idiopathic atrial fibrillation (AF).
METHODS: A cohort of 136 unrelated patients with idiopathic atrial fibrillation and 200 unrelated, ethnically
matched healthy controls were enrolled. The coding exons and splice junctions of the Nkx2.5 gene were
sequenced in 136 atrial fibrillation patients, and the available relatives of mutation carriers and 200 controls
were subsequently genotyped for the identified mutations. The functional characteristics of the mutated
Nkx2.5 gene were analyzed using a dual-luciferase reporter assay system.
RESULTS: Two novel heterozygous Nkx2.5 mutations (p.N19D and p.F186S) were identified in 2 of the 136
unrelated atrial fibrillation cases, with a mutational prevalence of approximately 1.47%. These missense
mutations co-segregated with atrial fibrillation in the families and were absent in the 400 control
chromosomes. Notably, 2 mutation carriers also had congenital atrial septal defects and atrioventricular block.
Multiple alignments of the Nkx2.5 protein sequences across various species revealed that the altered amino
acids were completely conserved evolutionarily. Functional analysis demonstrated that the mutant Nkx2.5
proteins were associated with significantly reduced transcriptional activity compared to their wild-type
counterpart.
CONCLUSION: These findings associate the Nkx2.5 loss-of-function mutation with atrial fibrillation and
atrioventricular block and provide novel insights into the molecular mechanism involved in the pathogenesis of
atrial fibrillation. These results also have potential implications for early prophylaxis and allele-specific therapy
of this common arrhythmia.
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& INTRODUCTION
Atrial fibrillation (AF) is the most common form of
sustained cardiac arrhythmia, accounting for approximately
one-third of hospital admissions for miscellaneous cardiac
rhythm conditions (1). The prevalence of AF is approxi-
mately 1% in the general population and increases with age,
rising from less than 1% in individuals aged under 60 years
to nearly 10% of those over 80 years of age (1). Among
people older than 40 years, the lifetime risk of developing
AF is approximately 25% (2). In the United States, the
number of persons with AF is currently estimated at 2.3
million and is projected to reach 15.9 million by 2050 (3).
This prevalent dysrhythmia is associated with decreased
quality of life, reduced exercise tolerance, impaired cogni-
tion, tachycardiomyopathy, thromboembolism, congestive
heart failure, and even death (1,4,5). Patients with AF have a
5-fold increased risk of ischemic stroke (6), and the mortality
rate of patients with AF is approximately 2-fold greater than
that of individuals with a normal sinus rhythm (7).
Therefore, AF confers a substantial economic burden on
both affected individuals and society (8). Despite the high
prevalence and clinical significance, the molecular etiology
of AF remains largely elusive.
Traditionally, AF has been thought of as a complication
secondary to various structural heart diseases or systemic
disorders, including ischemic heart disease, rheumatic heart
disease, congenital heart disease, cardiomyopathy, conges-
tive heart failure, essential hypertension, and hyperthyroid-
ism (1,9,10). However, in 30% to 45% of patients, AF occurs
separately in the absence of underlying diseases or
precipitating factors, which is a condition defined as
idiopathic or lone AF; at least 15% of these patients have a
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positive family history, termed familial AF (11). Increasing
epidemiological evidence has demonstrated the familial
aggregation of AF and the enhanced susceptibility to AF in
close relatives of patients with AF, strongly suggesting that
genetic components play pivotal roles in the initiation and
maintenance of AF in a subset of cases (12). Genome-wide
linkage analyses have mapped specific susceptibility loci for
AF on human chromosomes 10q22, 6q14-16, 11p15.5, 5p15,
10p11-q21, and 5p13; in particular, AF-causative mutations
in 2 genes, namely KCNQ1 on chromosome 11p15.5 and
NUP155 on chromosome 5p13, were identified and func-
tionally characterized (13). Direct scans of candidate genes
revealed a long list of AF-associated genes, including
KCNE2, KCNH2, KCNJ2, KCNA5, SCN5A, ANP, and
GJA5 (13). Nevertheless, AF has substantial genetic hetero-
geneity, and the genetic determinants for AF in most cases
remain to be identified.
It is well established that focal triggered activity is involved
in both the initiation and maintenance of AF and that the
myocardial sleeves surrounding the pulmonary veins at their
junctions with the atrial chambers are the predominant
source of ectopic activity (14). Recent studies have further
highlighted the critical role for several transcription factors,
including Nkx2.5, GATA4, GATA5, and GATA6, in the
normal embryonic development of the cardiovascular system
(15-17); in addition, variations in GATA4, GATA5, and
GATA6 have been causally linked to the pathogenesis of AF
(18-26). Cardiac-specific Nkx2.5 is a member of the NK2
family of homeodomain-containing transcription factors, and
its expression and functions overlap with those of GATA4,
GATA5, and GATA6 during cardiovascular genesis, espe-
cially in the regulation of target gene expression synergisti-
cally with GATA4 (27), which justifies screening for Nkx2.5
as a prime candidate gene for idiopathic AF.
& MATERIALS AND METHODS
Ethics statement
This investigation was conducted in compliance with the
ethical principles of the revised Declaration of Helsinki
(Somerset West, Republic of South Africa, 1996). The
research protocol was reviewed and approved by the local
institutional ethics committee, and written informed consent
was obtained from all of the participants prior to the study.
Study subjects
A cohort of 136 unrelated patients with idiopathic AF was
recruited from the Han Chinese population. The available
relatives of the patients harboring the identified Nkx2.5
mutations were also included. In total, 200 ethnically
matched, unrelated healthy individuals were enrolled as
controls. Peripheral venous blood samples were prepared,
and clinical data including medical records, electrocardio-
grams, and echocardiography reports were collected. The
study subjects were clinically classified using a consistently
applied set of definitions (11,23).
Mutational scan
Genomic DNA was extracted from the peripheral venous
blood lymphocytes of all participants using the Wizard
Genomic DNA Purification Kit (Promega, Madison, WI,
USA). The coding exons and exon-intron boundaries of
Nkx2.5 were sequenced in 136 unrelated patients with
idiopathic AF. Subsequently, genotyping of Nkx2.5 in the
available relatives of mutation carriers and 200 control
individuals was performed to detect the presence of
mutations that were identified in the probands. The
referential genomic DNA sequence of Nkx2.5 was derived
from GenBank (accession No. NT_023133) at the National
Center for Biotechnical Information (NCBI; http://www.
ncbi.nlm.nih.gov/). With the aid of Primer 3 software
(http://frodo.wi.mit.edu), the primer pairs used to amplify
the entire coding region and the splice junction sites of
Nkx2.5 by polymerase chain reaction (PCR) were designed
as previously described (28). PCR was performed using
HotStar Taq DNA Polymerase (Qiagen, Hilden, Germany)
with a Veriti Thermal Cycler (Applied Biosystems, Foster
City, CA, USA), and standard conditions and reagent
concentrations were used. The amplified products were
analyzed on 1% agarose gels stained with ethidium bromide
and purified using a QIAquick Gel Extraction Kit (Qiagen).
Both strands of each amplicon were sequenced with a
BigDyeH Terminator v3.1 Cycle Sequencing Kit (Applied
Biosystems) and an ABI PRISM 3130 XL DNA Analyzer
(Applied Biosystems). The sequencing primers were the
same as those previously designed for specific region
amplification. The DNA sequences were then analyzed
using DNA Sequencing Analysis Software v5.1 (Applied
Biosystems). Each variant was validated by re-sequencing
an independent PCR-generated amplicon from the subject
and met the quality control thresholds, with a call rate that
was greater than 99%. In addition, the novelty of each
identified sequence variant was confirmed by querying the
Exome Variant Server (EVS; http://evs.gs.washington.edu/
EVS) and NCBI’s single nucleotide polymorphism (SNP;
http://www.ncbi.nlm.nih.gov/SNP) online databases.
Alignment of multiple Nkx2.5 protein sequences
Multiple Nkx2.5 protein sequences across various species
were aligned using the program MUSCLE version 3.6
(http://www.ncbi.nlm.nih.gov/).
Prediction of the disease-causing potential of an
Nkx2.5 sequence variation
The causative potential of an Nkx2.5 sequence variation
was predicted using MutationTaster (available at http://
www.mutationtaster.org), which automatically assigned a
probability for the variation to be either a pathogenic
mutation or a benign polymorphism. Notably, the P value
used was the probability of the correct prediction rather than
the probability of error, as is used in t-test statistics (i.e., a
value close to 1 indicated high accuracy of the prediction).
Expression plasmids and site-directed mutagenesis
The recombinant expression plasmid Nkx2.5-pEFSA and
the atrial natriuretic factor (ANF)-luciferase reporter plas-
mid, which contains the 2,600-bp 5’-flanking region of the
ANF gene, referred to as ANF(-2600)-Luc, were provided by
Dr. Ichiro Shiojima from the Department of Cardiovascular
Science and Medicine, Chiba University Graduate School of
Medicine, Chuo-ku, Chiba, Japan. Each of the identified
mutations was introduced into wild-type Nkx2.5 using
a QuickChange II XL Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA, USA) with a complementary pair
of primers. The mutants were sequenced to confirm the
desired mutations and to exclude any other sequence
variations.
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Luciferase reporter gene assay
COS-7 cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum. The ANF(-
2600)-Luc reporter construct and an internal control reporter
plasmid pGL4.75 (hRluc/CMV, Promega) were used in
transient transfection assays to explore the transactivational
activity of the Nkx2.5 mutants. The COS-7 cells were transfected
with 0.4 mg of wild-type or mutant Nkx2.5-pEFSA expression
vector or empty vector pEFSA, 1.0 mg of ANF(-2600)-Luc
reporter construct, and 0.04 mg of pGL4.75 control reporter
vector using the Lipofectamine 2000 Transfection Reagent
(Invitrogen, Carlsbad, CA, USA). For the co-transfection
experiments, 0.2 mg of wild-type Nkx2.5-pEFSA, 0.2 mg of
mutant Nkx2.5-pEFSA or empty vector pEFSA, 1.0 mg of
ANF(-2600)-Luc, and 0.04 mg of pGL4.75 were used. Firefly
luciferase and Renilla luciferase activities were measured using
the Dual-Glo luciferase assay system (Promega) 48 h after
transfection. The activity of the ANF promoter was expressed as
the fold activation of Firefly luciferase relative to Renilla
luciferase. A minimum of 3 independent experiments was
performed for wild-type or mutant Nkx2.5.
Statistical analysis
The data are expressed as the means ¡ SD. Continuous
variables were tested for their normality of distribution, and
the Student9s unpaired t-test was used to compare numeric
variables between 2 groups. The categorical variables were
compared between 2 groups using Pearson’s chi-squared
test or Fisher9s exact test, when appropriate. A 2-sided P-
value less than 0.05 was considered statistically significant.
& RESULTS
Clinical characteristics of the study population
A cohort of 136 unrelated patients with idiopathic AF was
enlisted, clinically evaluated, and compared to 200 ethni-
cally matched, unrelated healthy individuals. None of the
subjects had traditional risk factors for AF. There were no
significant differences between the patient and control
groups regarding the baseline characteristics, including
age, gender, body mass index, blood pressure, fasting blood
glucose, serum lipids, left atrial dimension, left ventricular
ejection fraction, heart rate at rest, and life style (data not
shown). The baseline clinical characteristics of the 136
patients with idiopathic AF are summarized in Table 1.
Nkx2.5 mutations
Two heterozygous missense mutations in Nkx2.5 were
identified in 2 of the 136 unrelated patients with idiopathic
AF. The total population prevalence of Nkx2.5 mutations,
based on the patient cohort, was approximately 1.47%.
Specifically, the substitution of guanine (G) for adenine (A)
in the first nucleotide of codon 19 (c.55A.G), which
predicted the transition of asparagine (N) into aspartic acid
(D) at amino acid 19 (p.N19D), was identified in the index
patient from family 1. In addition, the change of thymine (T)
to cytosine (C) in the second nucleotide of codon 186
(c.557T.C), corresponding to the transversion of phenyla-
lanine (F) into serine (S) at amino acid 186 (p.F186S), was
found in the proband from family 2. The sequence
chromatograms displaying the detected heterozygous
Nkx2.5 mutations of c.55A.G and c.557T.C in contrast to
the control sequences are presented in Figure 1A and
Figure 1B, respectively. A schematic diagram of Nkx2.5
depicting the putative structural domains and location of
the mutations identified in the AF patients is presented in
Figure 1C. The missense mutations were neither observed in
the control population nor reported in the EVS and NCBI
SNP databases. Genetic scans of the available family
members of the mutation carriers revealed that, in each
family, the mutation was present in all of the living, affected
family members but was absent in the unaffected family
members examined. Analysis of the pedigrees demon-
strated that, in each family, the mutation that co-segregated
with AF was transmitted in an autosomal dominant pattern
with complete penetrance. The pedigree structures of the 2
families are illustrated in Figure 1D. The phenotypic
characteristics and the results of genetic screening of the
affected family members are listed in Table 2.
Interestingly, congenital atrial septal defect and pro-
gressive atrioventricular block were confirmed in indivi-
dual I-1 and individual II-1 from family 2 according to
previous echocardiograms and electrocardiograms, as
well as their medical history. Individual I-1 had an atrial
ostium secundum septal defect, paroxysmal AF, a second-
degree Wenchebach-type atrioventricular block, and an
incomplete right bundle branch block at the age of 35
years. He subsequently developed a third-degree atrio-
ventricular block and a complete right bundle branch
block, and a pacemaker was implanted at age 49.
Individual II-1 had a small atrial ostium secundum septal
defect, paroxysmal AF, and a first-degree atrioventricular
block at age 38. A pacemaker was implanted at age 46
after several syncopal episodes that were ascribed to
third-degree atrioventricular block. One young individual
(III-2) was an apparently asymptomatic mutation carrier.
However, Holter monitoring revealed paroxysmal AF and
Table 1 - Baseline clinical characteristics of the 136







Age at the initial diagnosis of AF
(years)
51.8 20–60
Age at the time of the present study
(years)
56.7 22–65
Type of AF at presentation
Paroxysmal AF 88 65
Persistent AF 27 20
Long-lasting persistent AF 21 15
Positive family history of AF 48 35
History of cardioversion 112 82
History of pacemaker 7 5
Resting heart rate (beats per minute) 76.5 58-160
Systolic blood pressure (mmHg) 126.4 90-136
Diastolic blood pressure (mmHg) 87.2 62-89
Body mass index (kg/m2) 22.4 20-24
Left atrial dimension (mm) 38 30-40
Left ventricular ejection fraction 0.6 0.5-0.7
Fasting blood glucose (mmol/L) 4.6 3.6-5.8
Total cholesterol (mmol/L) 4.0 3.0-5.6






Calcium channel blocker 11 8
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an intermittent first-degree atrioventricular block. No
sinus node dysfunction was observed in the studied
individuals from these 2 families.
In addition, 2 previously reported Nkx2.5 sequence
polymorphisms, namely c.63A.G and c.606C.G, were
observed in the AF patients and control individuals.
However, there was no significant difference in either of
the 2 allele frequencies between the AF patients and the
control groups. All of the sequence variants and their allele
frequencies are listed in Table 3.
Alignments of multiple Nkx2.5 protein sequences
across species
A cross-species alignment of the Nkx2.5 protein
sequences revealed that the altered amino acids were
completely conserved evolutionarily (Figure 2).
Figure 1 - Nkx2.5 mutations associated with idiopathic AF. A, Sequence electropherograms showing the c.55A.G mutation of Nkx2.5 in
contrast to the control. The arrow indicates the heterozygous nucleotides of A/G in the index patient from family 1 (mutant) or the
homozygous nucleotides of A/A in the corresponding control individual (wild-type). The rectangle designates the nucleotides
comprising a codon of Nkx2.5. B, Sequence electropherograms showing the c.557T.C mutation of Nkx2.5 in contrast to the control.
The arrow denotes the heterozygous nucleotides of T/C in the proband from family 2 (mutant) or the homozygous nucleotides of T/T in
the corresponding control individual (wild-type). C, Schematic representation of the Nkx2.5 protein structure, with the AF-related
mutations indicated. The mutations identified in patients with idiopathic AF are shown above the structural domains. NH2, amino-
terminus; TN, transcriptional activation domain; HD, homeodomain; NK, NK2-specific domain; and COOH, carboxyl-terminus. D,
Pedigree structures of the families with AF. The families are designated as family 1 and family 2, and the family members are identified
by generations and numbers. Squares indicate male family members; circles, female members; a symbol with a slash, a deceased
member; closed symbols, affected members; open symbols, unaffected members; arrows, probands; ‘‘+’’, carriers of the heterozygous
mutations; and ‘‘2’’, non-carriers.
Nkx2.5 mutations in AF
Xie WH et al.
CLINICS 2013;68(6):777-784
780
Disease-causing potential of the Nkx2.5 variation
The Nkx2.5 sequence variations of c.55A.G and
c.557T.C were both automatically predicted to be disease-
causing mutations, with p-values of 0.977377 and 0.999997,
respectively. No SNPs in the altered regions were found in
the MutationTaster database.
Transcriptional activity of the Nkx2.5 mutants
The same amounts of wild-type (0.4 mg), N19D-mutant
(0.4 mg), and F186S-mutant (0.4 mg) Nkx2.5 activated the
ANF promoter by ,13-fold, ,6-fold, and ,3-fold increase,
respectively, when compared with the empty plasmid.
When the same amount of wild-type Nkx2.5 (0.2 mg) was
cotransfected with N19D-mutant Nkx2.5 (0.2 mg) or F186S-
mutant Nkx2.5 (0.2 mg), the induced activation of the ANF
promoter was ,7-fold and ,5-fold increase, respectively,
in comparison with the empty plasmid (Figure 3).
& DISCUSSION
In the present study, 2 novel heterozygous Nkx2.5
mutations, p.N19D and p.F186S, were identified in 2 AF
families. In each family, the mutant allele was present in all
of the available, affected family members but was absent in
the unaffected relatives examined and in the 400 control
chromosomes. A cross-species alignment of the Nkx2.5
protein sequences revealed that the altered amino acids
were completely conserved evolutionarily, and functional
analysis demonstrated that the Nkx2.5 mutant proteins
were associated with significantly decreased transcriptional
activity. Therefore, it is highly probable that functionally
impaired Nkx2.5 contributes to AF in these families.
The human Nkx2.5 gene maps to chromosome 5q34, which
consists of 2 exons encoding a protein of 324 amino acids (29).
Nkx2.5 is highly expressed in the early cardiac progenitor cells in
both primary and secondary heart fields during embryogenesis
and continues to be expressed at a high level in the heart
throughout adulthood, thereby playing a crucial role in normal
cardiovascular genesis and maturation (15). The functional and
structural domains of Nkx2.5 are presumed to comprise the
amino-terminal TN domain, the homeodomain that recognizes
and binds to the specific consensus DNA sequence 59-T[C/
T]AAGTG-39, and the carboxy terminal NK2-specific domain
(Figure 1C). The TN and NK domains function to regulate the
transcriptional activity of Nkx2.5, whereas the homeodomain is
essential for nuclear translocation, DNA binding, and interac-
tions with other transcription factors (30). The p.N19D and
p.F186S mutations in Nkx2.5 identified in current study are
located in the TN domain and in the homeodomain,
respectively; thus, these mutations may be expected to exert
influence on the transcriptional activity of Nkx2.5 by direct
transcriptional inhibition or by interfering with its nuclear
distribution or DNA-binding ability.
Previous studies have demonstrated that Nkx2.5 serves as
an upstream regulator of multiple target genes that are
expressed in the heart during embryogenesis, including the
genes that encode ANF, brain natriuretic peptide, and a-
cardiac actin (31). Hence, the functional effect of an Nkx2.5
mutation could be characterized by analysis of the tran-
scriptional activity of the ANF promoter in cells expressing
mutated Nkx2.5 in comparison to its wild-type counterpart.
In the present study, the functional characteristics of the 2
novel Nkx2.5 mutations identified in AF patients were
analyzed using transcriptional activity assays, and the
results demonstrated significantly decreased transcriptional
activity of a downstream gene. These findings imply that
dysfunctional, mutated Nkx2.5 may serve as a potential
alternative pathological mechanism of AF.
The findings that functionally compromised Nkx2.5 con-
fers susceptibility to AF may be partially due to the abnormal
development of the pulmonary venous myocardium. The
pulmonary venous vessel is sheathed by a layer of
Table 2 - Phenotypic characteristics and the Nkx2.5 mutation status of the affected pedigree members.





















II-1 M 52 45 Long-lasting persistent 98 396/465 38 65 +/–
Family 2 F186S
I-1 M 65a 46 Long-lasting persistent 120 408/427 46 58 N/A
II-1 M 46 32 Persistent 110 388/450 42 65 +/–
II-5 M 40 35 Paroxysmal 104 438/482 40 62 +/–
II-8 F 38 38 Paroxysmal 88 418/424 37 68 +/–
III-2 M 22 22 Paroxysmal 86 382/424 32 64 +/–
Note: AF = atrial fibrillation; F = female; M = male; N/A = not available or not applicable; LAD = left atrial dimension; LVEF = left ventricular ejection
fraction; QT = QT interval; QTc = corrected QT interval. + indicates present and – denotes absent. a Age at death.
Table 3 - Nkx2.5 sequence variations identified in this study.
Location Nucleotide Amino acid Allele frequency
Patients Controls
Exon 1 c.55A.G p.N19D (0.004) 1/272 (0.000) 0/400
Exon 1 c.63A.G p.E21E (0.246) 67/272 (0.238) 95/400
Exon 2 c.557T.C p.F186S (0.004) 1/272 (0.000) 0/400
Exon 2 c. 606C.G p.L202L (0.022) 6/272 (0.020) 8/400
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myocardium known as the pulmonary myocardial sleeve,
which has been implicated in the initiation and maintenance
of AF by several potential electrophysiological mechanisms,
encompassing enhanced intrinsic pacemaker activity, aniso-
tropic arrangement of the myocardial fibers, and slowed
conduction that facilitates reentry (32-35). Genetic labeling
and lineage-tracing investigations have revealed that Nkx2.5
is abundantly expressed in the atria and the pulmonary
myocardium but is indispensable for the localized formation
of the sinoatrial node during embryogenesis. As a repressor
of the sinoatrial node lineage gene program, Nkx2.5 may
limit pacemaker activity to the sinoatrial and atrioventricular
nodes. In a hypomorphic model demonstrating reduced
Nkx2.5 protein expression, pulmonary cardiomyocytes were
shown to transition into connexin40-negative, HCN4-posi-
tive cells and adopt a nodal-like phenotype with pacemaker
activity (34). In Nkx2.5-null mouse embryos, HCN4 is
activated along the entire embryonic heart tube, whereas
connexin40 expression is suppressed, and ectopic pacemaker
cells are present throughout the heart (35). Therefore, a
Nkx2.5 loss-of-function mutation presumably predisposes an
individual to formation of the pulmonary myocardium
sleeve and switching of the pulmonary myocardium to a
Figure 2 - Alignment of the multiple Nkx2.5 protein sequences across species. The altered amino acids of p.N19 and p.F186 are
completely conserved evolutionarily among the various species.
Figure 3 - Functional defects resulting from Nkx2.5 mutations.
Activation of the atrial natriuretic factor promoter-driven
luciferase reporter in COS-7 cells by wild-type (WT), N19D-
mutant, or F186S-mutant Nkx2.5, alone or in combination,
demonstrated significantly decreased transactivational activity
of the mutant proteins. The experiments were performed in
triplicate, and the mean and standard deviations are shown.
* represents p,0.0005 when compared to wild-type Nkx2.5.
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sinoatrial node-like phenotype, thereby creating an atrial
arrhythmogenic substrate liable to AF.
It has been confirmed that certain downstream genes are
transactivated by Nkx2.5, and mutations in multiple target
genes have been linked to AF, including ANF, GATA4,
GATA5, GATA6, connexin40, and connexin43 (13,18-26).
Therefore, mutated Nkx2.5 may enhance susceptibility to
AF by down-regulating the expression of target genes.
Notably, congenital atrial septal defect and progressive
atrioventricular conduction block were documented in some
of the AF patients who carried the p.F186S mutation in
Nkx2.5. Similarly, congenital cardiovascular malformations
and progressive atrioventricular conduction block have
been previously associated with diverse Nkx2.5 mutations,
and the most common phenotypes caused by Nkx2.5
mutations include atrial septal defects and atrioventricular
block (36). These observational results suggest that a
proportion of AF cases may share a common genetic origin
with congenital heart disease and atrioventricular block.
In conclusion, the present study links the Nkx2.5 loss-of-
function mutation to AF and atrioventricular block. These
results provide novel insight into the molecular mechanisms
of AF and have potential implications for early prophylaxis
and allele-specific treatment of this common arrhythmia.
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